mct.aacrjournals.orgHome | Molecular Cancer Therapeutics

Skip to main content AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Molecular Cancer Therapeutics Register Log in My Cart Advertisement Main menu Home About The Journal AACR Journals Subscriptions Permissions and Reprints Reviewing Articles OnlineFirst Current Issue Past Issues Meeting Abstracts Collections COVID-19 & Cancer Resource Center Focus on Radiation Oncology Novel Combinations Reviews Editors' Picks "Best of" Collection For Authors Information for Authors Author Services Best of: Author Profiles First Disclosures Submit Alerts Table of Contents Editors' Picks OnlineFirst Citation Author/Keyword My Alert Summary & Preferences News Cancer Discovery News COVID-19 Search More Search for this keyword Advanced Search AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Clinical Cancer Research Molecular Cancer Research Molecular Cancer Therapeutics User menu Register Log in My Cart Search Search for this keyword Advanced search Home About The Journal AACR Journals Subscriptions Permissions and Reprints Reviewing Articles OnlineFirst Current Issue Past Issues Meeting Abstracts Collections COVID-19 & Cancer Resource Center Focus on Radiation Oncology Novel Combinations Reviews Editors' Picks "Best of" Collection For Authors Information for Authors Author Services Best of: Author Profiles First Disclosures Submit Alerts Table of Contents Editors' Picks OnlineFirst Citation Author/Keyword My Alert Summary & Preferences News Cancer Discovery News COVID-19 Search More Search for this keyword Advanced Search The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff. Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available . Announcing our new Impact Factor: 5.615 The research community’s source for first disclosures of cancer drug candidates. . -- October 2020 Read the October issue! Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis Smruthi Vijayaraghavan, et al. Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo Yamini M. Ohol, et al. Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy Christian K. Werner, et al. 1 2 3 4 From the Current Issue Review Ion Channels and Their Role in the Pathophysiology of Gliomas Takeshi Takayasu , Kaoru Kurisu , Yoshua Esquenazi and Leomar Y. Ballester Mol Cancer Ther October 1 2020 19 (10) 1959-1969; DOI:10.1158/1535-7163.MCT-19-0929 Small Molecule Therapeutics Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo Yamini M. Ohol , Michael T. Sun , Gene Cutler , Paul R. Leger , Dennis X. Hu , Berenger Biannic , Payal Rana , Cynthia Cho , Scott Jacobson , Steve T. Wong , Jerick Sanchez , Niket Shah , Deepa Pookot , Betty Abraham , Kyle Young , Silpa Suthram , Lisa A. Marshall , Delia Bradford , Nathan Kozon , Xinping Han , Akinori Okano , Jack Maung , Christophe Colas , Jacob Schwarz , David Wustrow , Dirk G. Brockstedt and Paul D. Kassner Mol Cancer Ther October 1 2020 19 (10) 1970-1980; DOI:10.1158/1535-7163.MCT-20-0184 Large Molecule Therapeutics | AuthorChoice Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis Smruthi Vijayaraghavan , Lorraine Lipfert , Kristen Chevalier , Barbara S. Bushey , Benjamin Henley , Ryan Lenhart , Jocelyn Sendecki , Marilda Beqiri , Hillary J. Millar , Kathryn Packman , Matthew V. Lorenzi , Sylvie Laquerre and Sheri L. Moores Mol Cancer Ther October 1 2020 19 (10) 2044-2056; DOI:10.1158/1535-7163.MCT-20-0071 Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers | AuthorChoice High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers Paul Riviere , Aaron M. Goodman , Ryosuke Okamura , Donald A. Barkauskas , Theresa J. Whitchurch , Suzanna Lee , Noor Khalid , Rachel Collier , Manvita Mareboina , Garrett M. Frampton , David Fabrizio , Andrew B. Sharabi , Shumei Kato and Razelle Kurzrock Mol Cancer Ther October 1 2020 19 (10) 2139-2145; DOI:10.1158/1535-7163.MCT-20-0161 Cancer Biology and Translational Studies Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy Christian K. Werner , Uchechi J. Nna , Hanshi Sun , Kari Wilder-Romans , Joseph Dresser , Ayesha U. Kothari , Weihua Zhou , Yangyang Yao , Arvind Rao , Stefanie Stallard , Carl Koschmann , Tarik Bor , Waldemar Debinski , Alexander M. Hegedus , Meredith A. Morgan , Sriram Venneti , Edwina Baskin-Bey , Daniel E. Spratt , Howard Colman , Jann N. Sarkaria , Arul M. Chinnaiyan , Joel R. Eisner , Corey Speers , Theodore S. Lawrence , Roy E. Strowd and Daniel R. Wahl Mol Cancer Ther October 1 2020 19 (10) 2163-2174; DOI:10.1158/1535-7163.MCT-20-0095 Models and Technologies Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis Joy M. Gary , John K. Simmons , Jinfei Xu , Shuling Zhang , Tyler J. Peat , Nicholas Watson , Benjamin J. Gamache , Ke Zhang , Alexander L. Kovalchuk , Aleksandra M. Michalowski , Jin-Qiu Chen , Tuddow Thaiwong , Matti Kiupel , Snehal Gaikwad , Maudeline Etienne , R. Mark Simpson , Wendy Dubois , Joseph R. Testa and Beverly A. Mock Mol Cancer Ther October 1 2020 19 (10) 2221-2232; DOI:10.1158/1535-7163.MCT-19-0671 See the Table of Contents Recent Reviews Reviews Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer Jill K. Jones and Eric M. Thompson Mol Cancer Ther September 1 2020 19 (9) 1763-1769; DOI:10.1158/1535-7163.MCT-20-0069 Reviews | AuthorChoice Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions Marna Williams , Anna Spreafico , Kapil Vashisht and Mary Jane Hinrichs Mol Cancer Ther September 1 2020 19 (9) 1770-1783; DOI:10.1158/1535-7163.MCT-19-0993 Review Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows Patrick J. Roberts , Vishnu Kumarasamy , Agnieszka K. Witkiewicz and Erik S. Knudsen Mol Cancer Ther August 1 2020 19 (8) 1575-1588; DOI:10.1158/1535-7163.MCT-18-1161 OnlineFirst Articles HuR in Pancreatic Cancer EMT Ruochen Dong , et al. LILRB4-targeting ADC for AML Therapy Yasuaki Anami , et al. Circulating Tumor Cells in Cervical Cancer Krishnansu S. Tewari , et al. CB-03–10 AR/GR Antagonist for AR-resistant Solid Tumors Caridad Rosette , et al. Load more Advertisement -- Back to top Home Alerts Feedback Privacy Policy Facebook Twitter LinkedIn YouTube RSS Articles Online First Current Issue Past Issues Meeting Abstracts Info for Authors Subscribers Advertisers Librarians Reviewers About MCT About the Journal Editorial Board Permissions Submit a Manuscript Copyright © 2020 by the American Association for Cancer Research. Molecular Cancer Therapeutics eISSN: 1538-8514 ISSN: 1535-7163 Advertisement...